Warren Barker

Mr. Warren Barker


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
RDRanjan Duara
Ranjan Duara
WBWarren Barker
Warren Barker

27 March 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
HCHelena Colvee
Helena Colvee
JPJuan David Rayo Parra
Juan David Rayo Parra
GGGabriel Antonio Gonzalez
Gabriel Antonio Gonzalez
WBWarren Barker
Warren Barker
RDRanjan Duara
Ranjan Duara
An improved understanding of the pathobiology of Alzheimer’s disease (AD) should lead ultimately to an earlier and more accurate diagnosis of AD, providing the opportunity to intervene earlier in the disease process and to improve outcomes. The known hallmarks of Alzheimer’s disease include amyloid-β plaques and neurofibrillary tau tangles. It is now clear that an imbalance between production and clearance of the amyloid beta protein and related Aβ peptides, especially Aβ42, is a very early, initiating factor in Alzheimer’s disease (AD) pathogenesis, leading to aggregates of hyperphosphorylation and misfolded tau protein, inflammation, and neurodegeneration. In this article, we review how the AD diagnostic process has been transformed in recent decades by our ability to measure these various elements of the pathological cascade through the use of imaging and fluid biomarkers. The more recently developed plasma biomarkers, especially phosphorylated-tau217 (p-tau217), have utility for screening and diagnosis of the earliest stages of AD. These biomarkers can also be used to measure target engagement by disease-modifying therapies and the response to treatment.

26 April 2018 in JMIR Medical Informatics
Verified
Journal Article
Open access
GLGabriel Lizarraga
Gabriel Lizarraga
CLChunfei Li
Chunfei Li
MCMercedes Cabrerizo
Mercedes Cabrerizo
WBWarren Barker
Warren Barker
DLDavid Loewenstein
David Loewenstein
Malek AdjouadiMalek Adjouadi
Malek Adjouadi
Clinical informatics, decision support for health professionals, electronic health records, and ehealth infrastructures.

4 September 2020 in Archives of Clinical Neuropsychology
Verified
Journal Article
Open access
PDF file
FAFernanda Arruda
Fernanda Arruda
MRMónica Rosselli
Mónica Rosselli
MGMaria T Greig
Maria T Greig
DLDavid Loewenstein
David Loewenstein
MLMerike Lang
Merike Lang
RDRanjan Duara
Ranjan Duara
To investigate the association between the functional activities questionnaire (FAQ) and brain biomarkers (bilateral hippocampal volume [HV], bilateral entorhinal volume [ERV], and entorhinal cortical thickness [ERT]) in cognitively normal (CN) individuals, mild cognitive impairment (MCI), or dementia. In total, 226 participants (137 females; mean age = 71.76, SD = 7.93; Hispanic Americans = 137; European Americans = 89) were assessed with a comprehensive clinical examination, a neuropsychological battery, a structural magnetic resonance imaging, and were classified as CN or diagnosed with MCI or dementia. Linear regression analyses examined the association between functional activities as measured by the FAQ on brain biomarkers, including HV, ERV, and ERT, controlling for age, education, global cognition, gender, and ethnicity. The FAQ significantly predicted HV, ERV, and ERT for the entire sample. However, this association was not significant for ERV and ERT when excluding the dementia group. The FAQ score remained a significant predictor of HV for the non-dementia group. Age, education, gender, ethnicity, Montreal Cognitive Assessment score, and FAQ were also significant predictors of HV for the overall sample, suggesting that younger Hispanic females with fewer years of education, higher global mental status, and better functioning, were more likely to have larger HV. FAQ scores were related to HV in older adults across clinical groups (CN, MCI, and dementia), but its association with the entorhinal cortex was driven by individuals with dementia. Demographic variables, including ethnicity, additionally influenced these associations.

12 November 2019 in Archives of Clinical Neuropsychology
Verified
Journal Article
Closed access
PDF file
MLMerike Lang
Merike Lang
MRMónica Rosselli
Mónica Rosselli
MGMaria T Greig
Maria T Greig
VTValeria L Torres
Valeria L Torres
IVIdaly Vélez-Uribe
Idaly Vélez-Uribe
RDRanjan Duara
Ranjan Duara
To analyze (1) whether there are ethnic differences in the severity of depressive symptoms between groups of elders classified as cognitively normal (CN) or amnestic mild cognitive impairment (aMCI) and (2) the influence of depressive symptoms on specific cognitive performance by ethnicity across diagnoses, controlling for covariates. 164 Hispanics residing in the United States (HAs) and European Americans (EAs) (100 women; Mage = 72.1, SD = 8.0) were diagnosed as either CN or aMCI. Depressive symptoms were measured with the Geriatric Depression Scale (GDS-15). Cognition was assessed using the Loewenstein-Acevedo Scales for Semantic Interference and Learning (semantic memory), Multilingual Naming Test (confrontation naming), and the Stroop Test (Color–Word condition; executive function). A 2 × 2 univariate ANCOVA as well as linear and logistic regressions explored differences in depressive symptoms among diagnostic and ethnic groups. Higher depression was seen in aMCI compared to the CN group for both ethnicities, after controlling for age, education, gender, and Mini-Mental State Examination score. Greater levels of depression also predicted lower scores in confrontation naming and semantic memory for only the EA group and marginally in scores of executive function for HA participants. GDS-15 scores of ≤ 4 also predicted less likelihood of aMCI diagnosis. Severity of depressive symptoms was associated with greater cognitive impairment, independent of ethnicity. Significant results suggest detrimental effects of depression on clinical diagnoses most evidently for subjects from the EA group.

19 December 2023 in Archives of Clinical Neuropsychology
Verified
Journal Article
Closed access
PDF file
IVIdaly Vélez-Uribe
Idaly Vélez-Uribe
MRMónica Rosselli
Mónica Rosselli
DNDavid Newman
David Newman
JGJoanna Gonzalez
Joanna Gonzalez
YPYaimara Gonzalez Pineiro
Yaimara Gonzalez Pineiro
RDRanjan Duara
Ranjan Duara
We aimed to evaluate the psychometric properties and diagnostic accuracy of the 32-item version of the Multilingual Naming Test (MINT) in participants from 2 ethnic groups (European Americans [EA; n = 106] and Hispanic Americans [HA; n = 175]) with 3 diagnostic groups (cognitively normal [CN], n = 94, mild cognitive impairment [MCI], n = 148, and dementia, n = 39). An Item Response Theory model was used to evaluate items across ethnicity and language groups (Spanish and English), resulting in a 24-item version. We analyzed the MINT discriminant and predictive validity across diagnostic groups. A total of 8 items were differentially difficult between languages in the 32-item version of the MINT. EA scored significantly higher than HA, but the difference was not significant when removing those 8 items (controlling for Education). The Receiver Operating Characteristics showed that the MINT had poor accuracy when identifying CN participants and was acceptable in identifying dementia participants but unacceptable in classifying MCI participants. Finally, we tested the association between MINT scores and magnetic resonance imaging volumetric measures of language-related areas in the temporal and frontal lobes. The 32-item MINT in English and Spanish and the 24-item MINT in Spanish were significantly correlated with the bilateral middle temporal gyrus. The left fusiform gyrus correlated with MINT scores regardless of language and MINT version. We also found differential correlations depending on the language of administration. Our results highlight the importance of analyzing cross-cultural samples when implementing clinical neuropsychological tests such as the MINT.